Theratechnologies to Host Key Opinion Leader Event to Discuss its SORT1+ Technology™ for the Treatment of All Sortilin-Expressing Cancers

Rhea-AI Summary

Theratechnologies has announced a KOL webinar scheduled for June 21, 2021, at 11:00 a.m. ET, focusing on their SORT1+ Technology™ and TH1902, an investigational peptide-drug conjugate for treating sortilin-expressing advanced solid tumors. The webinar will feature Dr. Richard Béliveau from Université du Québec à Montréal and updates from the company's executives. Notably, TH1902 has received fast track designation from the FDA for advanced solid tumors that are resistant to standard therapy, and it is currently in a Phase 1 clinical trial.

- Webinar on Monday, June 21, 2021 at 11:00 a.m. ET -

MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will host a key opinion leader (KOL) webinar on the Company’s SORT1+ Technology™ and TH1902, its lead investigational peptide-drug conjugate (PDC) for treating sortilin-expressing advanced solid tumors, on Monday, June 21, 2021 at 11:00 a.m. Eastern Time.

To register for the webinar, please go to: https://lifesci.rampard.com/WebcastingAppv5/Events/Registration/registration.jsp?Y2lk=MTE5MQ==.

The webinar will feature a presentation by KOL Richard Béliveau, Ph.D., Université du Québec à Montréal, who will discuss the science of receptor-mediated cancer therapy and the discovery of sortilin as a novel target in cancer treatment. Dr. Béliveau will be available to answer questions following the formal presentations. Theratechnologies' President and Chief Executive Officer Paul Lévesque and Senior Vice President and Chief Medical Officer Christian Marsolais, Ph.D. will also give an update on its oncology program.

SORT1+ Technology™ is a new class of cancer treatment targeting all sortilin-expressing cancers by linking approved anticancer drugs to a proprietary peptide that specifically binds to the sortilin receptor. The PDC is internalized by the sortilin receptor and the therapeutic agent is released directly inside the cancer cell.

TH1902 was granted fast track designation by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy and is currently being evaluated in a Phase 1 clinical trial.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

For media inquiries:
Denis Boucher
Vice-President, Communications and Corporate Affairs
514-336-7800

For investor inquiries:
Leah Gibson
Senior Director, Investor Relations
ir@theratech.com
617-356-1009

FAQ

What is the purpose of the webinar hosted by Theratechnologies on June 21, 2021?

The webinar will discuss Theratechnologies' SORT1+ Technology™ and TH1902 for treating sortilin-expressing advanced solid tumors.

Who will present at the Theratechnologies webinar on June 21, 2021?

Dr. Richard Béliveau will present, along with updates from CEO Paul Lévesque and CMO Christian Marsolais.

What is TH1902 and its significance in cancer treatment?

TH1902 is a peptide-drug conjugate targeting sortilin-expressing advanced solid tumors and has received FDA fast track designation.

At what time is the Theratechnologies webinar on June 21, 2021?

The webinar will start at 11:00 a.m. ET.

How can I register for the Theratechnologies webinar?

You can register for the webinar by visiting the provided registration link in the press release.